D. Pettitt

发表

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

T. MacDonald, S. Morant, J. Goldstein, 2003, Gut.

Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine.

A. Walker, J. Yeaw, S. Robbins, 2006, Journal of the American Society of Nephrology : JASN.

Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey.

Gurkirpal Singh, Jeffrey D. Miller, M. Russell, 2002, The American journal of managed care.

Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.

D. Huse, R. D'Agostino, Gurkirpal Singh, 2003, The Journal of rheumatology.

Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus

E. Vittinghoff, D. Bauer, A. Karter, 2006, Annals of Internal Medicine.

Does Synchronizing Initiation of Therapy Affect Adherence to Concomitant Use of Antihypertensive and Lipid-Lowering Therapy?

J. Schwartz, T. Mclaughlin, N. Rosenberg, 2009, American journal of therapeutics.

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin

J. McMurray, J. Caro, A. Mcguire, 1997, BMJ.

Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.

E. Rahme, J. LeLorier, D. Pettitt, 2002, Arthritis and rheumatism.

Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.

J. Schwartz, N. Maniadakis, J. Goldstein, 2000, Rheumatology.

Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both

J. Schwartz, T. Mclaughlin, D. Pettitt, 2003 .

Modifications in Response to Poorly Controlled Hypertension , Dyslipidemia , and Diabetes Mellitus

E. Vittinghoff, D. Bauer, A. Karter, 2008 .

Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.

J. Schwartz, T. MacDonald, D. Pettitt, 2003, Rheumatology.

The cost-effectiveness of preventing initial coronary events with pravastatin

J. Caro, A. Mcguire, J. Norrie, 1997 .

Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.

F. Wolfe, D. Pettitt, Sean Z. Zhao, 2004, The Journal of rheumatology.

Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.

Sean Hennessy, David J Margolis, Rita Schinnar, 2003, The New England journal of medicine.

Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.

F. Wolfe, T. Burke, L. Arguelles, 2002, The Journal of rheumatology.

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study.

B. Astor, J. Coresh, G. Heiss, 2006, American heart journal.

Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease.

J. Griffith, H. Tighiouart, A. Levey, 2005, Journal of the American Society of Nephrology : JASN.

A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis

N. Maniadakis, T. Burke, J. Goldstein, 2012, PharmacoEconomics.

OP0138 Relative gastrointestinal toxicity of cox-2 specific and traditional nsaids in a high-risk population from a health maintenance organisation

J. Schwartz, J. Goldstein, T. Burke, 2001 .

Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics

D. Margolis, W. Bilker, S. Hennessy, 2004 .

A predictive model of hospitalisation and death from chronic obstructive pulmonary disease.

T. MacDonald, P. Thompson, J. Winter, 2009, Respiratory medicine.

Impact of self-rated osteoarthritis severity in an employed population: Cross-sectional analysis of data from the national health and wellness survey

M. Dibonaventura, S. Silverman, Shaloo Gupta, 2012, Health and Quality of Life Outcomes.

Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.

F. Wolfe, T. Burke, L. Arguelles, 2002, The Journal of rheumatology.

High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population.

S. Sidney, A. Karter, J. Selby, 2004, The American journal of managed care.

The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis.

K. Lapane, J. Spooner, D. Pettitt, 2001, The American journal of managed care.

Determinants of acetaminophen (A) utilization versus traditional NSAIDs

E. Rahme, D. Pettitt, J. Lorier, 2000, American Journal of Gastroenterology.

International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.

J. Caro, A. Mcguire, J. Norrie, 1999, European heart journal.

Is paclitaxel and cisplatin a cost‐effective first‐line therapy for advanced ovarian carcinoma?

A. Covens, D. Pettitt, K. Roche, 1996, Cancer.

Strategies for the Management of Hypercholesterolaemia: A Systematic Review of the Cost-Effectiveness Literature

J. Caro, A. Mcguire, S. Morris, 1997, Journal of health services research & policy.